Your session is about to expire
← Back to Search
Oncolo-GIST for Cancer (Oncolo-GIST Trial)
N/A
Waitlist Available
Led By Holly G Prigerson, PhD
Research Sponsored by Weill Medical College of Cornell University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 week post-scan, 2 months post-scan, 4 months post-scan.
Awards & highlights
Oncolo-GIST Trial Summary
This trial will help to improve the way oncologists communicate with their patients who only have months left to live by teaching them to relay information both sensitively and using simple terminology.
Eligible Conditions
- Cancer
- Critical Illness
- Communication
Oncolo-GIST Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1 week post-scan, 2 months post-scan, 4 months post-scan.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 week post-scan, 2 months post-scan, 4 months post-scan.
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change in Prognostic Understanding
Secondary outcome measures
Patient Performance Status
Patient Quality of Life
Treatment and Care Received
+1 moreOncolo-GIST Trial Design
4Treatment groups
Experimental Treatment
Placebo Group
Group I: Oncolo-GIST Arm - PhysiciansExperimental Treatment1 Intervention
Physicians assigned to this arm will receive the Oncolo-GIST training intervention.
Group II: Oncolo-GIST Arm - PatientsExperimental Treatment1 Intervention
Patients assigned to this arm will discuss scan results revealing progressive disease with an Oncolo-GIST trained physician.
Oncolo-GIST: Behavioral: Oncolo-GIST Oncolo-GIST is a brief, manualized communication intervention that guides oncologists in "gist communication" by itemizing 4 key steps in the process of imparting prognostic information.
Topics covered include:
Principles of introducing prognosis in the setting of worsened scan results Coupling communicating realistic prognoses with psychological support (e.g., saying "average life-expectancy is months…" with emphasizing that the oncology team "will always provide care for you") Addressing informational needs and psychological reactions Applying proven techniques for supporting patients who are reluctant to discuss prognosis.
Group III: Usual Care Arm - PatientsPlacebo Group1 Intervention
Patients assigned to this arm will will discuss scan results revealing progressive disease with a physician that was not trained with the Oncolo-GIST intervention.
Usual Care Arm: Oncologists will provide care in non-specific manner.
Group IV: Usual Care Arm - PhysiciansPlacebo Group1 Intervention
Physicians assigned to this arm will not receive the Oncolo-GIST training intervention.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Oncolo-GIST
2020
N/A
~60
Find a Location
Who is running the clinical trial?
Weill Medical College of Cornell UniversityLead Sponsor
1,055 Previous Clinical Trials
1,316,258 Total Patients Enrolled
National Institute of Nursing Research (NINR)NIH
580 Previous Clinical Trials
10,376,524 Total Patients Enrolled
Holly G Prigerson, PhDPrincipal InvestigatorWeill Medical College of Cornell University
3 Previous Clinical Trials
29 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is recruitment currently open for this clinical experimentation?
"As per the clinicaltrials.gov listing, this trial is not enrolling patients at this time. This research was introduced on October 25th 2020 and most recently revised on August 11th 2022. However, 229 other studies are currently searching for participants to join their trials."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger